Bulletin from Moberg Pharma’s AGM on May 18th, 2021

Bulletin from Moberg Pharma’s AGM on May 18^th, 2021

STOCKHOLM, May 18^th, 2021. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.

Adoption of the income statements and the balance sheets
The Annual General Meeting approved the income statements and the balance sheets for the fiscal year July 2019 to December 2020.

The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors that no dividend should be paid for the fiscal year July 2019 to December 2020.

The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal year July 2019 to December 2020.

Board of Directors
In accordance with the proposal of the Nomination Committee, the Annual General Meeting resolved that the Board of Directors shall consist of four persons and no deputies.

The Annual General Meeting resolved re-election of Peter Wolpert, Mattias Klintemar and Fredrik Granström as well as new election of Nikolaj Sörensen for a period until the end of the next Annual General Meeting.

The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that an aggregate annual fee of SEK 870,000 shall be paid to the Board members, of which SEK 360,000 to the Chairman of the Board of Directors and SEK 170,000 to each of the other Board members elected by the General Meeting. In order to compensate for the additional work that Peter Wolpert will perform in the Company in the capacity of executive Chairman of the Board, the Annual General Meeting also resolved on a fee of SEK 30,500 per month to Peter Wolpert (a total of SEK 366,000 annually, and together with ordinary fees for the Chairman of the Board of Directors SEK 726,000).

Fees to the Auditors, for a period until the end of the next Annual General Meeting, are to be paid as per approved invoice.

Nomination Committee
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that the Company shall have a Nomination Committee consisting of four members. The Nomination Committee shall comprise one representative of each of the three largest shareholders or owner groups in the Company in terms of votes as per September 30^th, 2021, besides the Chairman of the Board of Directors.

Principles for remuneration
The Annual General Meeting resolved to approve the Board of Director’s proposal for principles of remuneration to senior executives in Moberg Pharma.

Remuneration report
The Annual General Meeting resolved to approve the Board of Director’s remuneration report in accordance with Chapter 8, Section 53a of the Swedish Companies Act.

Implementation of LTI 2021
The Annual General Meeting also resolved to approve the Board of Director’s proposal to implement a long-term incentive program, including transfer of up to 1,344,000 ordinary shares to the participants and other hedging arrangements in respect of the program, including authorization for the Board of Directors to resolve on a directed issue and repurchase of up to 1,344,000 class C shares.

Amendments to the articles of association
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors, to change the articles of association regarding the limits of the share capital and the number of shares.

The Annual General Meeting authorized the Board of Directors, the CEO or whomever the Board of Directors appoints, to make such minor adjustments and clarifications regarding the Annual General Meeting’s resolution that may prove necessary in connection with the registration with the Companies Registration Office.

Authorization to issue shares
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors, to authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders’ pre-emptive rights, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company’s share capital by issuing new shares in the Company. The total number of shares issued in accordance with this authorisation may be equivalent to a maximum of twenty (20) per cent of the shares in the Company at the time of the Annual General Meeting.

The Annual General Meeting authorized the Board of Directors, the CEO or whomever the Board of Directors appoints, to make such minor adjustments and clarifications regarding the Annual General Meeting’s resolution that may prove necessary in connection with the registration with the Companies Registration Office and Euroclear.

Minutes from the meeting and complete resolutions
The minutes from the Annual General Meeting will be made available at the Company and on the Company’s website, www.mobergpharma.com.

Post voting procedure
To prevent the spread of the virus that causes Covid-19, the Extraordinary General Meeting was conducted via a post voting procedure and thus without physical presence of shareholders, proxies or external parties.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@moberpharma.se

About this information
The information was submitted for publication at 1.00 p.m. on May 18^th 2021 through the contact persons above.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's intention is to submit a registration application during the second half of 2021 in Europe. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).